18 March 2019 - Systemic sclerosis, also known as scleroderma, is a rare chronic connective tissue disease.

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease with the FDA and EMA. 

Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis.

Read Boehringer Ingelheim press release